Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2019 - 2026)

Ginkgo Bioworks Holdings' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $14.9 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 55.69% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (down 55.69% YoY) and the FY2025 annual result came in at $94.1 million, down 25.61% from the prior year.
• Current Deferred Revenue was $14.9 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $94.1 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $222.6 million in Q4 2022 and bottomed at $14.9 million in Q1 2026.
• A 5-year average of $80.3 million and a median of $42.8 million in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue jumped 368.98% — and 2024, when it sank 80.56%.
• Ginkgo Bioworks Holdings' Current Deferred Revenue stood at $222.6 million in 2022, then retreated by 9.03% to $202.5 million in 2023, then plunged by 37.53% to $126.5 million in 2024, then dropped by 25.61% to $94.1 million in 2025, then slumped by 84.16% to $14.9 million in 2026.
• Business Quant data shows DNA's Current Deferred Revenue at $14.9 million in Q1 2026, $94.1 million in Q4 2025, and $25.2 million in Q3 2025.